Eisai And Merck & Co Supercharge Lenvima's Potential

A global collaboration potentially valued at nearly $6bn will see Eisai's oral tyrosine kinase inhibitor lenvatinib being evaluated in combination with Keytruda in multiple cancer types and indications.